These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 31649109)

  • 41. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalizing
    Falcomatà C; Schneider G; Saur D
    Cancer Discov; 2020 Jan; 10(1):23-25. PubMed ID: 31919121
    [No Abstract]   [Full Text] [Related]  

  • 43. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
    Parajuli P; Singh P; Wang Z; Li L; Eragamreddi S; Ozkan S; Ferrigno O; Prunier C; Razzaque MS; Xu K; Atfi A
    EMBO J; 2019 Jul; 38(13):e101067. PubMed ID: 31268604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
    Viale A; Pettazzoni P; Lyssiotis CA; Ying H; Sánchez N; Marchesini M; Carugo A; Green T; Seth S; Giuliani V; Kost-Alimova M; Muller F; Colla S; Nezi L; Genovese G; Deem AK; Kapoor A; Yao W; Brunetto E; Kang Y; Yuan M; Asara JM; Wang YA; Heffernan TP; Kimmelman AC; Wang H; Fleming JB; Cantley LC; DePinho RA; Draetta GF
    Nature; 2014 Oct; 514(7524):628-32. PubMed ID: 25119024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anticipating resistance to KRAS inhibition: a novel role for USP21 in macropinocytosis regulation.
    Crawford HC
    Genes Dev; 2021 Oct; 35(19-20):1325-1326. PubMed ID: 34599002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
    Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
    Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
    Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macroautophagy/autophagy promotes resistance to KRAS
    Han L; Meng L; Liu J; Xie Y; Kang R; Klionsky DJ; Tang D; Jia Y; Dai E
    Cancer Lett; 2024 Nov; 604():217258. PubMed ID: 39276914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting mTOR dependency in pancreatic cancer.
    Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
    Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.
    Asahina K; Balog S; Hwang E; Moon E; Wan E; Skrypek K; Chen Y; Fernandez J; Romo J; Yang Q; Lai K; French SW; Tsukamoto H
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G265-G276. PubMed ID: 31760766
    [No Abstract]   [Full Text] [Related]  

  • 55. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
    Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
    Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
    [No Abstract]   [Full Text] [Related]  

  • 57. Differential Cell Susceptibilities to Kras
    Shi C; Pan FC; Kim JN; Washington MK; Padmanabhan C; Meyer CT; Kopp JL; Sander M; Gannon M; Beauchamp RD; Wright CV; Means AL
    Cell Mol Gastroenterol Hepatol; 2019; 8(4):579-594. PubMed ID: 31310834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
    Duan X; Zhang T; Feng L; de Silva N; Greenspun B; Wang X; Moyer J; Martin ML; Chandwani R; Elemento O; Leach SD; Evans T; Chen S; Pan FC
    Cell Stem Cell; 2024 Jan; 31(1):71-88.e8. PubMed ID: 38151022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.
    Parameswaran N; Bartel CA; Hernandez-Sanchez W; Miskimen KL; Smigiel JM; Khalil AM; Jackson MW
    Sci Rep; 2019 Sep; 9(1):13396. PubMed ID: 31527715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.
    Wang X; Breuer J; Garbe S; Giordano F; Brossart P; Feldmann G; Bisht S
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.